Combined General Meeting of April 2, 2024
Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, will hold its Combined General Meeting (CGM) on April 2, 2024 at 2pm at Sorbonne Université- 4 Place Jussieu, 75005 Paris.
The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales Obligatoires (BALO) no. 19 of February 12, 2024, and an amending notice was published in BALO no. 24 of February 23, 2024.
Information and preparatory documents for this General Meeting, including the voting form, are available on the Company’s website (https://www.biophytis.com/en/action/assemblees-generales/biophytis- annual-general-meeting-2024/)
Shareholders are strongly encouraged to vote in advance of the CGM, by (i) post, (ii) appointing the Chairman of the meeting as proxy, or (iii) via the secure online platform VOTACCESS.
Votes must be submitted no later than three days before the general meeting (i.e. March 30, 2024) for proxy votes or postal votes and the day before for proxy votes or postal votes via VOTACCESS (i.e. April 1, 2024).